Drug Information

Drug General Information
Drug ID
D0D8ZK
Former ID
DNCL002071
Drug Name
OBP-301
Indication Breast cancer; Head and neck cancer; Liver cancer [ICD9: 174, 175, 140-149, 140-229, 155, 203.0; ICD10:C50, C07-C14, C32-C33, C22] Phase 1/2 [525003]
Company
Oncolys Biopharma
Target and Pathway
Target(s) Telomerase reverse transcriptase Target Info Inhibitor [526935]
NetPath Pathway IL2 Signaling Pathway
Pathway Interaction Database Validated targets of C-MYC transcriptional activation
Regulation of Telomerase
IL2 signaling events mediated by PI3K
Regulation of nuclear beta catenin signaling and target gene transcription
HIF-1-alpha transcription factor network
Reactome Formation of the beta-catenin:TCF transactivating complex
References
Ref 525003ClinicalTrials.gov (NCT02293850) Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma. U.S. National Institutes of Health.
Ref 526935Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.